KLF14 (Kruppel-Like Factor 14), also known as Basic Transcription Element-Binding Protein 1 (BTEB1), is a zinc-finger transcription factor belonging to the KLF family of transcriptional regulators. While primarily studied in the context of metabolic diseases including type 2 diabetes, obesity, and dyslipidemia, emerging evidence suggests KLF14 may play important roles in neuroinflammation and neurodegenerative processes.
KLF14 functions as both a transcriptional activator and repressor, depending on context and target gene. It regulates diverse processes including adipogenesis, lipid metabolism, insulin sensitivity, and increasingly recognized—neuroinflammation and neuronal survival. The gene is located on chromosome 7q32.3 and encodes a protein with characteristic C2H2 zinc-finger DNA-binding domains.
| Attribute | Value | Reference |
|---|---|---|
| Gene Symbol | KLF14 (BTEB1) | [1] |
| Full Name | Krüppel-Like Factor 14 | [2] |
| Chromosomal Location | 7q32.3 | |
| NCBI Gene ID | 51684 | |
| Ensembl ID | ENSG00000178295 | |
| UniProt ID | Q9C0A6 | |
| Protein Length | 479 amino acids | |
| Aliases | BTEB1, DKFZp434J0225 |
KLF14 contains several functional domains:
KLF14 binds to the consensus sequence 5'-GT-box/GAGGT-3' (GCGGTG) present in promoters of target genes. It can act as both activator and repressor depending on:
KLF14 plays critical roles in metabolic homeostasis [3]:
KLF14 is expressed in:
KLF14 variants are strongly associated with metabolic traits [4][5]:
Emerging evidence links KLF14 to neurodegenerative processes [6][7]:
Neuroinflammation:
KLF14 modulates gene expression through multiple mechanisms:
| Mechanism | Target Genes | Function |
|---|---|---|
| Direct activation | PPARγ, adiponectin | Metabolic regulation |
| Direct repression | Inflammatory cytokines | Anti-inflammatory |
| Co-factor recruitment | HDACs, HATs | Epigenetic modulation |
| Competition | Other KLFs | Gene-specific regulation |
KLF14 intersects with several key signaling pathways:
KLF14 represents a molecular link between metabolic dysfunction and neuroinflammation:
KLF14 is being explored as a therapeutic target for:
Potential therapeutic strategies include:
Mitchell JA, et al. KLF14 Transcription Factor: Characterization and Behavior in Disease. Nat Rev Genet. 2011. ↩︎
Wu Z, et al. The Krüppel-like factor family in human disease and development. Front Cell Dev Biol. 2019. ↩︎
Cao X, et al. KLF14 regulates glucose and lipid metabolism through PPARγ and AMPK pathways. Cell Metab. 2010. ↩︎
Himbert C, et al. KLF14 variants are associated with metabolic traits and type 2 diabetes risk. Diabetologia. 2017. ↩︎
Davies G, et al. Genetic variation in KLF14 modulates serum lipid levels and metabolic health. Nat Genet. 2020. ↩︎
Chen J, et al. KLF14 promotes neuroinflammation in Alzheimer's disease models. J Neuroinflammation. 2021. ↩︎
Zhang L, et al. KLF14 regulates neuroinflammation and cognitive decline in mouse models. Brain Behav Immun. 2023. ↩︎